【摘要】 目的探讨丁苯酞对急性缺血性脑卒中患者淋巴细胞亚群变化情况的影响。方法选取2017年1月~2018年12月期间在本院就诊的99例急性缺血性脑卒中患者,分为对照组(n=48)和研究组(n=51),对照组接受常规治疗,研究组在常规治疗基础上联合使用丁苯酞软胶囊。于治疗前后测定淋巴细胞亚群变化情况,同时对脑梗死面积、Barthel指数、美国国立卫生研究院脑卒中量表(NIHSS)评分进行比较,计算不良反应发生率。结果治疗后两组CD3+、CD4+、CD4+/CD8+水平较治疗前明显上升(P<0.05),且治疗后研究组CD3+、CD4+、CD4+/CD8+水平明显高于对照组(P<0.05);治疗后两组脑梗死面积较治疗前均明显变小(P<0.05),Barthel指数评分较治疗前均明显增大(P<0.05),NIHSS评分较治疗前均明显减小(P<0.05),且治疗后研究组脑梗死面积小于对照组(P<0.05),Barthel指数评分大于对照组(P<0.05),NIHSS评分小于对照组(P<0.05);研究组不良反应发生率(1.96%)与对照组不良反应发生率(4.17%)比较,差异无统计学意义(P>0.05)。结论急性缺血性脑卒中使用丁苯酞,则CD3+、CD4+、CD8+水平改善程度更加明显,细胞免疫功能恢复良好,缩小脑梗死面积,改善神经功能缺损,恢复日常生活能力,安全性好。更多还原

【Abstract】 Objective To explore the effect of butylphthalide on lymphocyte subsets in patients with acute ischemic stroke. Methods 99 patients with acute ischemic stroke treated in our hospital from January 2017 to December 2018 were divided into two groups: Control group(n=48) and study group(n=51). The control group received routine treatment,while the study group used butylphthalide soft capsule on the basis of routine treatment. The changes of lymphocyte subsets were detected before treatment. At the same time, the area of cerebral infarction, Barthel index(BI) and National Institutes of Health Stroke Scale(NIHSS) scores were compared between the two groups, and the incidence of adverse reactions was calculated. Results After treatment, the levels of CD3+, CD4+, CD4+/CD8+of two groups were significantly higher than those before treatment(P<0.05), and the levels of CD3+, CD4+, CD4+/CD8+in the study group were significantly higher than those in the control group(P<0.05); the area of cerebral infarction in the two groups after treatment were significantly smaller than that before treatment(P<0.05), BI score was significantly higher than that before treatment(P<0.05), NIHSS score was significantly lower than that before treatment(P<0.05), and the area of cerebral infarction in the study group was significantly smaller than that in the control group(P<0.05), BI score was significantly higher than that in the control group(P<0.05), NIHSS score was significantly lower than that in the control group(P<0.05); the incidence of adverse reactions in the study group was 1.96%, which was significantly lower than that in the control group(4.17%), the difference was significant(P>0.05). Conclusion The application of butylphthalide for acute ischemic strokec can significantly improve the level of CD3+, CD4+, CD8+, recover the cellular immune function, reduce the area of cerebral infarction, improve the neurological function defect, restore the ability of daily life, and it has a good safety.更多还原